Stereoselective interaction between piroxicam and acenocoumarol

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 525-530

  Bonnabry, P ^a   Desmeules, J ^a   Rudaz, S ^b   Leemann, T ^a   Veuthey, J L ^b   Dayer, P ^a  

^a University Hospital   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

acenocoumarol; anticoagulants; cytochrome P 450; drug interaction; NSAIDs; piroxicam

Indexed keywords

ACENOCOUMAROL; PIROXICAM;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOCHEMISTRY;

EID: 0029991765     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03558.x     Document Type: Article

References (26)

1. Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-1875.
2. Freedman MD. Oral anticoagulants: Pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32: 196-209.
3. Godbillon J, Richard J, Gerardin A, Meinertz T, Kasper W, Jähnchen E. Pharmacokinetics of the enantiomers of acenocoumarol in man. Br J Clin Pharmacol 1981; 12: 621-629.
4. Holford NH. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504.
5. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5: 54-59.
6. Hermans JJR, Thijssen HHW. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 1993; 110: 482-490.
7. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175: 1112-1118.
8. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
9. Leemann TD, Transon C, Bonnabry P, Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exptl Clin Res 1993; 19: 189-195.
10. Zhao J, Leemann T, Dayer P. In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sci 1992; 51: 575-581.
11. Kondo M, Leemann T, Dayer P. Piroxicam 5′-hydroxylation is catalyzed by human cytochrome P450TB (CYP2C). Experientia 1992; 48: A7.
12. Leemann T, Transon C, Dayer P. Cytochrome P450TB (CYP2C): a major monooxygenase catalysing diclofenac 4′-hydroxylation in human liver. Life Sci 1993; 52: 29-34.
13. Bonnabry P, Leemann T, Dayer P. Biotransformation by hepatic P450TB (CYP2C) controls mefenamic acid elimination. Clin Pharmacol Ther 1994; 55: 139.
14. Leemann T, Bonnabry P, Dayer P. Stereo- and nonstereoselective oxidation by P450TB (CYP2C): the major elimination pathway of (±)-ibuprofen. Clin Pharmacol Ther 1994; 55: 208.
15. Lewis RJ, Trager W, Chan KK, et al. Warfarin - Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest 1974; 53: 1607-1617.
16. Banfield C, O'Reilly R, Chan E, Rowland M. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-675.
17. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. Drug Intell Clin Pharm 1985; 19: 556-558.
18. Mallet L, Cooper, JW. Prolongation of prothrombin time with the use of piroxicam and warfarin. Can J Hosp Pharm 1991; 44: 93-94.
19. Desprez D, Blanc P, Larrey D, Michel H. Hémorragie digestive favorisée par une hypocoagulation excessive due à une interaction médicamenteuse piroxicam-antagoniste de la vitamine K. Gastroenterol Clin Biol 1992; 16: 906-907.
20. Fitos I, Visy J, Simonyi M, Hermansson J. Stereoselective distribution of acenocoumarol enantiomers in human plasma: chiral chromatographic analysis of the ultrafiltrates. Chirality 1993; 5: 346-349.
21. Gill TS, Hopkins KJ, Rowland M. Stereospecific assay of nicoumalone: application to pharmacokinetics studies in man. Br J Clin Pharmacol 1988; 25: 591-598.
22. Benveniste C, Striberni R, Dayer P. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam. Eur J Clin Pharmacol 1990; 38: 547-549.
23. Gill TS, Hopkins KJ, Bottomley J, Gupta SK, Rowland M. Cimetidine-nicoumalone interaction in man: stereochemical considerations. Br J Clin Pharmacol 1989; 27: 469-474.
24. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
25. Gascon MP, Dayer P. In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 1991; 41: 573-578.
26. Tassaneeyakul W, Birkett DJ, Veronese ME, et al. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 1993; 265: 401-407.